Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability.
[primary effusion lymphoma]
Human
herpesvirus
8
(
HHV-
8
)
infection
is
associated
with
Kaposi
's
sarcoma
,
primary
effusion
lymphoma
(
PEL
)
,
and
multicentric
Castleman
's
disease
.
HHV-
8
-
encoded
viral
interleukin-
6
(
vIL-
6
)
is
believed
to
contribute
to
pathogenesis
via
proproliferative
,
antiapoptotic
,
and
proangiogenic
activities
.
In
PEL
cells
,
vIL-
6
is
produced
in
functional
amounts
during
viral
latency
and
promotes
the
growth
of
these
cells
,
mediating
its
activity
from
the
endoplasmic
reticulum
(
ER
)
,
where
it
is
predominantly
localized
.
This
vIL-
6
activity
is
dependent
,
in
part
,
on
its
interaction
with
a
splice
variant
of
vitamin
K
epoxide
reductase
complex
subunit
1
(
VKORC
1
)
,
termed
VKORC
1
variant
2
(
VKORC
1
v
2
)
.
Here
we
report
that
the
IL
-
6
signal
transducer
,
gp
130
,
which
can
support
vIL-
6
signaling
from
the
ER
,
is
also
required
for
optimal
PEL
cell
growth
and
viability
.
Levels
of
activated
extracellular
regulated
kinases
(
ERKs
)
1
and
2
and
signal
transducer
and
activator
of
transcription
1
(
STAT
1
)
and
STAT
3
,
phosphorylated
following
gp
130
stimulation
,
were
reduced
in
gp
130
-
depleted
BCBL-
1
and
BC
-
1
cells
.
Diminished
STAT
activation
was
also
detected
in
JSC-
1
and
BC
-
3
cells
.
Effects
of
gp
130
depletion
on
growth
could
be
mimicked
by
short
hairpin
RNA
targeting
of
ERKs
1
and
2
or
by
depletion
of
STAT
3
.
Finally
,
inhibition
of
vIL-
6
-
gp
130
association
specifically
within
the
ER
compartment
suppressed
cell
proliferation
and
viability
,
mirroring
the
effects
of
gp
130
depletion
.
Combined
,
these
data
demonstrate
that
gp
130
,
in
addition
to
VKORC
1
v
2
,
is
essential
for
normal
PEL
cell
growth
and
survival
and
that
ER-
localized
vIL-
6
-
gp
130
interactions
are
critical
for
these
activities
.
Targeting
of
intracellular
vIL-
6
-
gp
130
interactions
could
potentially
provide
a
means
of
PEL
therapy
.
Diseases
Validation
Diseases presenting
"localized vil-6"
symptom
primary effusion lymphoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom